Improving IPF care for Veterans with a new, practical care model
Official title: IMPLEMENT-IPF: Improving Management Practices and Leveraging Expertise for iNitiating Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Funded at Durham VA Medical Center · NIH-11345476 · Data updated 2026-11-12
A project to help Veterans with idiopathic pulmonary fibrosis get timely, expert, and age-friendly care using a new care model.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Durham VA Medical Center NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | October 1, 2026 |
| Project end | September 30, 2031 |
| Funding year | 2027 |
| NIH project number | 1IK2RD000415-01A2 |
| Project ID | NIH-11345476 on NIH RePORTER |
Who could benefit from this research
✓Could help
Veterans with idiopathic pulmonary fibrosis who receive care through VA systems and are affected by IPF.
✕Less likely to help
Patients outside the VA system or without IPF are unlikely to directly benefit.
What this research studies
This project aims to design and test a multilevel care model that makes IPF treatment more accessible for Veterans and integrates geriatric considerations. It focuses on barriers to receiving antifibrotics, pulmonary rehabilitation, and palliative care in real-world VA settings. The work will use VA data and collaboration across VA teams to implement practical improvements in care delivery. The goal is to translate evidence-based practices into routine care that fits the needs of older Veterans with IPF.
Why it matters
Potential benefit: If successful, Veterans with IPF could receive faster, more comprehensive, and age-appropriate treatments.
How similar studies have gone: Past studies show that implementing real-world care models can improve access to antifibrotic therapies and supportive care in IPF, though results vary by setting.
Where this research is happening
-
Durham VA Medical Center
Durham, United States Active
Researchers
- Principal investigator: Guidot, Daniel Marshall — Durham VA Medical Center
- Study coordinator: Guidot, Daniel Marshall
Related research
Other NIH-funded projects on the same topics.
-
New oral medicine targeting a pathway to treat idiopathic pulmonary fibrosis
This study is looking at a new pill that could help people with idiopathic pulmonary fibrosis (IPF) by targeting a specific pathway in the body, aiming to provide a safer and more effective treatment than what’s currently available.
-
New treatment targeting IL-17A for idiopathic pulmonary fibrosis
This study is exploring a new treatment for idiopathic pulmonary fibrosis (IPF) that aims to reduce inflammation in the lungs, which could help improve lung function and quality of life for people living with this condition.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.